Literature DB >> 30043522

Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas.

Thing Rinda Soong1, Brooke E Howitt2, Alexander Miron3, Neil S Horowitz4, Frank Campbell3, Colleen M Feltmate4, Michael G Muto4, Ross S Berkowitz4, Marisa R Nucci1, Wa Xian5, Christopher P Crum1.   

Abstract

The distal Fallopian tube is a site of origin for many 'ovarian' high-grade serous carcinomas (HGSCs) with intraepithelial carcinomas (STICs) that share identical TP53 mutations with metastatic tumors. TP53 mutation-positive early serous proliferations (ESPs) comprise a spectrum including p53 signatures and serous tubal intraepithelial lesions (STILs) and are not considered malignant; however, ESPs are often the only abnormality found in Fallopian tubes of women with metastatic HGSC. The purpose of this study was to determine if a relationship exists between isolated ESPs and concurrent metastatic HGSCs in the absence of STIC. Fallopian tubes from 32 HGSCs without a co-existing STIC/HGSC in the endosalpinx were exhaustively sectioned. The presence of either STIC/HGSC or ESP in the endosalpinx was documented and DNA from tissues containing ESPs, concurrent HGSC, and control epithelia were interrogated for TP53 mutations by targeted amplicon-based sequencing with average coverage reads >4000 across DNA replicate samples. Serial sectioning revealed a previously unrecognized STIC/HGSC in 3 of 32 (9.3%) and ESPs in 13 (40.6%). Twelve contained TP53 mutations. Nine (75%) shared identical TP53 mutations with concurrent HGSCs, four at high (≥ 5%) and five at low (< 5%) allele frequency. All control epithelia were TP53 mutation-negative. This study, for the first time, indicates lineage identity between ESPs in the distal tube and some metastatic HGSCs via a shared site-specific TP53 mutation. It supports a novel serous carcinogenic sequence in which an ESP could eventually culminate in a metastatic serous cancer via 'precursor escape' and would explain the apparent sudden onset of cancers without co-existing STICs. This paradigm for serous cancer development underscores the likelihood that multiple precursor types in the Fallopian tube contribute to serous cancer development with implications for the evolution, pathologic classification, and prevention of this lethal malignancy.
Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  Fallopian tube; TP53; high-grade serous carcinoma; lineage; precancer; serous tubal intraepithelial carcinoma

Mesh:

Substances:

Year:  2018        PMID: 30043522     DOI: 10.1002/path.5145

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

1.  Reduced PAX2 expression in murine fallopian tube cells enhances estrogen receptor signaling.

Authors:  Jose A Colina; Peter Varughese; Subbulakshmi Karthikeyan; Amrita Salvi; Dimple A Modi; Joanna E Burdette
Journal:  Carcinogenesis       Date:  2020-07-10       Impact factor: 4.944

Review 2.  Synthetic Lethality in Ovarian Cancer.

Authors:  Akshaya Chandrasekaran; Kevin M Elias
Journal:  Mol Cancer Ther       Date:  2021-09-13       Impact factor: 6.261

Review 3.  Advancements in Microfluidic Systems for the Study of Female Reproductive Biology.

Authors:  Vedant V Bodke; Joanna E Burdette
Journal:  Endocrinology       Date:  2021-10-01       Impact factor: 4.736

Review 4.  Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations.

Authors:  Isao Otsuka
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

5.  Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis.

Authors:  Lara Paracchini; Chiara Pesenti; Martina Delle Marchette; Luca Beltrame; Tommaso Bianchi; Tommaso Grassi; Alessandro Buda; Fabio Landoni; Lorenzo Ceppi; Cristina Bosetti; Mariachiara Paderno; Marco Adorni; Debora Vicini; Patrizia Perego; Biagio Eugenio Leone; Maurizio D'Incalci; Sergio Marchini; Robert Fruscio
Journal:  JAMA Netw Open       Date:  2020-07-01

6.  Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.

Authors:  Eric J Norris; Qing Zhang; Wendell D Jones; Darla DeStephanis; Ashley P Sutker; Chad A Livasy; Ram N Ganapathi; David L Tait; Mahrukh K Ganapathi
Journal:  J Pathol       Date:  2019-05-14       Impact factor: 7.996

Review 7.  zzm321990 MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer.

Authors:  Megan L Hutchcraft; Holly H Gallion; Jill M Kolesar
Journal:  Diagnostics (Basel)       Date:  2021-01-06

Review 8.  Screening and Prevention for High-Grade Serous Carcinoma of the Ovary Based on Carcinogenesis-Fallopian Tube- and Ovarian-Derived Tumors and Incessant Retrograde Bleeding.

Authors:  Isao Otsuka; Takuto Matsuura
Journal:  Diagnostics (Basel)       Date:  2020-02-22

Review 9.  Molecular Trajectory of BRCA1 and BRCA2 Mutations.

Authors:  Yuichiro Hatano; Maho Tamada; Mikiko Matsuo; Akira Hara
Journal:  Front Oncol       Date:  2020-03-25       Impact factor: 6.244

10.  A Novel Mapping Strategy Utilizing Mouse Chromosome Substitution Strains Identifies Multiple Epistatic Interactions That Regulate Complex Traits.

Authors:  Anna K Miller; Anlu Chen; Jacquelaine Bartlett; Li Wang; Scott M Williams; David A Buchner
Journal:  G3 (Bethesda)       Date:  2020-12-03       Impact factor: 3.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.